Celestia S. Higano
Fred Hutchinson Cancer Research Center
465 Papers
3.4K Citations
Celestia S. Higano is an academic researcher from Fred Hutchinson Cancer Research Center. The author has contributed to research in topics: Prostate cancer & Medicine. The author has an hindex of 78, co-authored 423 publications. Previous affiliations of Celestia S. Higano include United States Department of Veterans Affairs & Ohio State University.
Chat about Author
Papers
Use of bone health agents (BHAs) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) after abiraterone (Abi): An interim review of REASSURE
Cora N. Sternberg,Bertrand Tombal,Kurt Miller,Fred Saad,Oliver Sartor,J. P. Sade,Christopher J. Logothetis,Joaquim Bellmunt,S. Dizdarevic,Lauren C. Harshman,John P Logue,Sergio Baldari,T. Richardson,D. Bottomley,Martin Schostak,Inga Bayh,J. Kalinovsky,Celestia S. Higano +17 more
TL;DR: This work presents a meta-analysis of 125 cases of Prostate Cancer in rats over a 10-year period that shows clear trends in prognosis and in particular in cases of high prostate cancer in women with high preponderance of Heterogeneity.
7
Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study)
Daniel J. George,Neeraj Agarwal,Oliver Sartor,Cora N. Sternberg,Bertrand Tombal,Fred Saad,Kurt Miller,Niculae Constantinovici,Helen Guo,John Reeves,Xiaolong Jiao,Per Sandström,F. Verholen,Celestia S. Higano,Neal D. Shore +14 more
TL;DR: The real-world EPIX study was conducted to gather information about the characteristics of patients with metastatic castration-resistant prostate cancer (mCRPC) who survived ≥2 years after treatment with the alpha-emitter radium-223 as discussed by the authors .
Genetic Factors Associated with Prostate Cancer Conversion from Active Surveillance to Treatment
Yu Jiang,Travis J. Meyers,Adaeze A. Emeka,Lauren Folgosa Cooley,Phillip R. Cooper,Nicola Lancki,Irene Helenowski,Linda Kachuri,Daniel W. Lin,Daniel W. Lin,Janet L. Stanford,Janet L. Stanford,Lisa F. Newcomb,Lisa F. Newcomb,Suzanne Kolb,Suzanne Kolb,Antonio Finelli,Neil E. Fleshner,Maria Komisarenko,James A. Eastham,Behfar Ehdaie,Nicole Benfante,Christopher J. Logothetis,Justin R. Gregg,Cherie Perez,Sergio Garza,Jeri Kim,Leonard S. Marks,Merdie Delfin,Danielle Barsa,Danny Vesprini,Laurence Klotz,Andrew Loblaw,Alexandre Mamedov,S. Larry Goldenberg,Celestia S. Higano,Maria Spillane,Eugenia Wu,H. Ballentine Carter,Christian P. Pavlovich,Mufaddal Mamawala,Tricia Landis,Peter R. Carroll,June M. Chan,Matthew R. Cooperberg,Janet E. Cowan,Todd M. Morgan,Javed Siddiqui,Rabia Martin,Eric A. Klein,Karen Brittain,Paige Gotwald,DA Barocas,Jeremiah R. Dallmer,Jeremiah R. Dallmer,Jennifer B. Gordetsky,Pam Steele,Shilajit Kundu,Jazmine Stockdale,Monique J. Roobol,Lionne D.F. Venderbos,Martin G. Sanda,Rebecca S. Arnold,Dattatraya Patil,Christopher P. Evans,Marc A. Dall'Era,Anjali Vij,Anthony J. Costello,Ken Chow,Niall M. Corcoran,Soroush Rais-Bahrami,Courtney Phares,Douglas S. Scherr,Thomas Flynn,R. Jeffrey Karnes,Michael O. Koch,Courtney Rose Dhondt,Joel B. Nelson,Dawn McBride,Michael S. Cookson,Kelly L. Stratton,Stephen Farriester,Erin Hemken,Walter M. Stadler,Tuula Pera,Deimante Banionyte,Fernando J. Bianco,Isabel H. Lopez,Stacy Loeb,Samir S. Taneja,Nataliya Byrne,Christopher L. Amling,Ann Martinez,Luc Boileau,Franklin Gaylis,Jacqueline Petkewicz,Nicholas Kirwen,Brian T. Helfand,Jianfeng Xu,Denise M. Scholtens,William J. Catalona,John S. Witte +101 more
TL;DR: In this article, a multi-institutional genome-wide association study (GWAS) of 6,361 PC patients who initially elected active surveillance and were followed over time for the potential outcome of conversion from AS to active treatment was conducted.
7
Sipuleucel-T in metastatic castration-resistant prostate cancer (mCRPC) patients ≥80 years-old: Data from PROCEED.
Chadi Nabhan,A. Oliver Sartor,Matthew R. Cooperberg,Andrew J. Armstrong,Jeffrey L. Vacirca,Raoul S. Concepcion,William R. Berry,Manish Dhawan,Ronald Tutrone,Andrew Sandler,Candice McCoy,James Boyd Whitmore,Robert Claude Tyler,Celestia S. Higano +13 more
TL;DR: Sipuleucel-T is an autologous cellular immunotherapy indicated for asymptomatic or minimally symptomatic mCRPC based on data from the pivotal phase 3 IMPACT trial that demonstrated a 22% reduction in the risk of death.
7
Phase II evaluation of amonafide in renal cell carcinoma. A Southwest Oncology Group study.
Celestia S. Higano,Phyllis J. Goodman,J B Craig,Julie A. Kish,Saul E. Rivkin,Michael K. Wolf,E D Crawford +6 more
TL;DR: In a phase II trial with amonafide 300-450 mg/m2/day on days 1-5 every 21 days, the median survival was 7.5 months as mentioned in this paper.
7